全文获取类型
收费全文 | 629篇 |
免费 | 44篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 17篇 |
妇产科学 | 9篇 |
基础医学 | 71篇 |
口腔科学 | 18篇 |
临床医学 | 83篇 |
内科学 | 135篇 |
皮肤病学 | 32篇 |
神经病学 | 15篇 |
特种医学 | 134篇 |
外科学 | 37篇 |
综合类 | 10篇 |
预防医学 | 37篇 |
眼科学 | 6篇 |
药学 | 26篇 |
肿瘤学 | 54篇 |
出版年
2023年 | 7篇 |
2021年 | 4篇 |
2020年 | 11篇 |
2019年 | 10篇 |
2018年 | 9篇 |
2017年 | 8篇 |
2016年 | 10篇 |
2015年 | 14篇 |
2014年 | 11篇 |
2013年 | 26篇 |
2012年 | 10篇 |
2011年 | 13篇 |
2010年 | 20篇 |
2009年 | 26篇 |
2008年 | 10篇 |
2007年 | 39篇 |
2006年 | 16篇 |
2005年 | 15篇 |
2004年 | 5篇 |
2003年 | 11篇 |
2002年 | 9篇 |
2001年 | 13篇 |
2000年 | 7篇 |
1999年 | 9篇 |
1998年 | 47篇 |
1997年 | 48篇 |
1996年 | 23篇 |
1995年 | 24篇 |
1994年 | 13篇 |
1993年 | 12篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 10篇 |
1989年 | 15篇 |
1988年 | 14篇 |
1987年 | 13篇 |
1986年 | 13篇 |
1985年 | 15篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 12篇 |
1979年 | 9篇 |
1975年 | 7篇 |
1971年 | 4篇 |
1968年 | 3篇 |
1944年 | 3篇 |
1941年 | 4篇 |
1937年 | 4篇 |
排序方式: 共有686条查询结果,搜索用时 375 毫秒
681.
Freytag F Schelling A Meinicke T Deichsel G;Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group 《Clinical therapeutics》2001,23(1):108-123
OBJECTIVE: This study was undertaken to compare the efficacy and tolerability of telmisartan, a novel antihypertensive agent, and atenolol, a well-established beta-blocker, in the treatment of mild to moderate hypertension. METHODS: This 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group, titration-to-response study compared doses of telmisartan (40 mg titrated to 80 mg titrated to 120 mg) with atenolol (50 mg titrated to 100 mg) required to achieve diastolic blood pressure (DBP) control (< or = 90 mm Hg or a decrease from baseline of > or = 10 mm Hg). Open-label hydrochlorothiazide (HCTZ) 12.5 or 25 mg was added if needed according to a prespecified titration rule. Men and women aged > 18 years with mild to moderate hypertension (morning mean supine DBP [SDBP] > or = 95 mm Hg and < or = 114 mm Hg) were eligible to participate. Patients with significant cardiovascular, metabolic, hepatic, or renal dysfunction or chronic obstructive pulmonary disease were excluded. The primary efficacy end point was trough SDBP response at 26 weeks; secondary efficacy end points included changes from baseline at trough in both standing and supine DBP and systolic blood pressure (SBP), and heart rate after 4, 8, 16, and 26 weeks; SBP control (reduction from baseline of > or = 10 mm Hg); normalization of supine SDBP to < or = 90 mm Hg; and the need for add-on HCTZ. Changes in quality of life were also examined. Adverse events were obtained from spontaneous reporting and recorded. Serious adverse events were reported to the sponsor according to predefined timelines. RESULTS: A total of 533 patients from 49 centers participated. Patients' mean age was 57.9 years (range, 22-79 years); 55.9% (298/533) of the population was male and 98.1% (523/533) was white. Of the 533 patients randomly assigned to treatment and included in the safety analysis, 520 (97.6%) were included in the efficacy analysis; 346 received telmisartan and 174 received atenolol. A total of 489 patients (91.7%) completed the study (325 [93.9%], telmisartan; 164 [94.2%], atenolol). Full SDBP response (trough SDBP < or = 90 mm Hg and/or a reduction from baseline of > or = 10 mm Hg) was observed in 84% and 78% of telmisartan- and atenolol-treated patients, respectively; this difference was not statistically significant. Final SBP/DBP reductions of 20.9/14.4 mm Hg were observed for the telmisartan regimen versus 16.7/13.3 mm Hg for the atenolol regimen; only the difference in SBP was significant (P = 0.005). Reduction from baseline in SBP of > or = 10 mm Hg was achieved by 80% of telmisartan-treated and 68% of atenolol-treated patients (P = 0.003). Adverse events were reported by 52.7% of patients given telmisartan and 61.2% of patients given atenolol; this difference was not statistically significant. Most events were mild or moderate. Although fatigue and male impotence were more common in atenolol-treated patients (3.4% and 4.0%, respectively), the incidence of these adverse events was too low to differentiate statistically. CONCLUSIONS: Telmisartan appears to be at least as effective as atenolol in the treatment of mild to moderate hypertension and may be better tolerated. 相似文献
682.
Lin Li Jing Wang Cheng-Cheng Tong Chi-Yi He 《Hepatobiliary & pancreatic diseases international : HBPD INT》2023,22(3):282-287
Background: The risk factors for the recurrent choledocholithiasis after endoscopic retrograde cholangiopancreatography(ERCP) have not been well studied. The aim of this study was to explore the risk factors of recurrent choledocholithiasis. Methods: We carried out a retrospective analysis of data collected between January 1, 2010 and January 1, 2020. Univariate analysis and multivariate analysis were used to explore the independent risk factors of recurrent choledocholithiasis following therape... 相似文献
683.
Storch Josephine Meissner Franziska Böde Monique Kwetkat Anja Pletz Mathias W. Freytag Antje 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2023,66(9):953-961
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Die Ständige Impfkommission empfiehlt eine jährliche Influenzaimpfung als Standardimpfung für... 相似文献
684.
Marcelo Germani DDS MSc Claudia C. M. S. Almeida DDS MSc Victor R. M. Munoz-Lora DDS PhD Victor Rogério DDS MSc Nicholas Moelhoff MD David L. Freytag MD Jeremy B. Green MD Michael Alfertshofer MD Kristina Davidovic MD Sebastian Cotofana MD PhD PhD 《Journal of Cosmetic Dermatology》2023,22(11):2950-2956
Background
A previous injection algorithm termed the “Toxin Lift” was recently introduced and described volume increases in the midface following neuromodulator treatments of the jawline. Increase in midfacial volume due to soft tissue repositioning could also affect the severity of infraorbital hollows.Objective
The objective is therefore to evaluate whether the severity of infraorbital hollows can be improved by injecting neuromodulators in the supra-mandibular segment of the platysma.Materials and Methods
A total of 35 volunteers (11 males/24 females) with a mean age of 39.8 (9.6) years and a mean BMI of 25.2 (5.2) kg/m2 were investigated. Bilateral infraorbital regions were evaluated via clinical assessment and semi-quantitative 3D imaging. The applied injection technique targeted the platysma via four injection points administering 5 I.U. per injection point resulting in a total of 20 I.U. per facial side.Results
Volume increase of the infraorbital region was 0.13 cc at 15 days (p = 0.001) and was 0.02 cc at 30 days (p = 0.452) whereas the skin displacement in cranial direction was 0.54 mm at 15 days (p < 0.001) and was 0.31 mm at 30 days (p < 0.001). Clinical evaluation revealed a highly statistically significant improvement of the tear trough, palpaebromalar groove, and of the lid-cheek junction when compared to baseline with all p < 0.001.Conclusion
The results of this clinical prospective interventional analysis revealed that the “Toxin Lift” injection technique is capable to improve the clinical appearance of infraorbital hollows. The effects can be explained by the concepts of facial biomechanics. 相似文献685.
Pavel Gelezhe MD PhD Konstantin Frank MD Gabriela Casabona MD Kai O. Kaye MD Samuel Kassirer Nicholas Moelhoff MD David L. Freytag MD Robert H. Gotkin MD Michael Alfertshofer MD Sebastian Cotofana MD PhD 《Journal of Cosmetic Dermatology》2023,22(11):2957-2963